4D Molecular Therapeutics, Inc. Operating Lease, Payments
4D Molecular Therapeutics, Inc. (FDMT) reported Operating Lease, Payments of $2.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. operating lease, payments for the quarter ending 2026-06-30 was $1.50M, a 7.14% increase year-over-year.
- 4D Molecular Therapeutics, Inc. operating lease, payments for the quarter ending 2026-03-31 was $1.40M, a 0.00% change year-over-year.
- 4D Molecular Therapeutics, Inc. operating lease, payments for the quarter ending 2025-12-31 was $1.40M, a 55.56% increase year-over-year.
- 4D Molecular Therapeutics, Inc. operating lease, payments for the quarter ending 2025-09-30 was $1.40M, a 75.00% increase year-over-year.
- 4D Molecular Therapeutics, Inc. operating lease, payments for fiscal 2025 was $5.60M, a 69.70% increase from fiscal 2024.
- 4D Molecular Therapeutics, Inc. operating lease, payments for fiscal 2024 was $3.30M, a 6.45% increase from fiscal 2023.
- 4D Molecular Therapeutics, Inc. operating lease, payments for fiscal 2023 was $3.10M, a 3.33% increase from fiscal 2022.
- 4D Molecular Therapeutics, Inc. operating lease, payments for fiscal 2022 was $3.00M, a 30.43% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.90M 10-Q · filed 2026-08-13 | $4.30M derived: sum of 3 quarters · filed 2026-08-13 | $5.70M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.40M 10-Q · filed 2026-05-07 | $2.80M derived: sum of 2 quarters · filed 2026-05-07 | $4.20M derived: sum of 3 quarters · filed 2026-05-07 | $5.60M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $2.80M derived: sum of 2 quarters · filed 2026-03-18 | $4.20M derived: sum of 3 quarters · filed 2026-08-13 | $5.60M 10-K · filed 2026-03-18 |
| 2025-09-30 | $1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $2.80M derived: sum of 2 quarters · filed 2026-08-13 | $4.20M 10-Q · filed 2025-11-10 | $5.10M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.80M 10-Q · filed 2026-08-13 | $3.70M derived: sum of 3 quarters · filed 2026-08-13 | $4.50M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.40M 10-Q · filed 2026-05-07 | $2.30M derived: sum of 2 quarters · filed 2026-05-07 | $3.10M derived: sum of 3 quarters · filed 2026-05-07 | $3.90M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $1.70M derived: sum of 2 quarters · filed 2026-03-18 | $2.50M derived: sum of 3 quarters · filed 2026-03-18 | $3.30M 10-K · filed 2026-03-18 |
| 2024-09-30 | $800.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $1.60M derived: sum of 2 quarters · filed 2025-11-10 | $2.40M 10-Q · filed 2025-11-10 | $3.20M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $800.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $1.60M 10-Q · filed 2025-08-11 | $2.40M derived: sum of 3 quarters · filed 2025-08-11 | |
| 2024-03-31 | $800.00K 10-Q · filed 2025-05-08 | $1.60M derived: sum of 2 quarters · filed 2025-05-08 | ||
| 2023-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $3.10M 10-K · filed 2025-02-28 | ||
| 2023-09-30 | $2.30M 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | $2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $3.00M 10-K · filed 2023-03-15 | ||
| 2022-09-30 | $100.00K 10-Q · filed 2022-11-08 | |||
| 2021-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $2.30M 10-K · filed 2022-03-28 | ||
| 2021-09-30 | $1.10M 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |